en Pediatric Hematology & Oncology Pediatric Hematology & Oncology پژوهشي Original Article <p>Langerhans cell histiocytosis (LCH) is a rare disorder described as three different entities including eosinophilic granuloma<br>of bone, the Hand-Schuller-Christian syndrome, and Letterer-Siwe disease. LCH is currently classified into single<br>system LCH, and multisystem LCH. Patients with single system LCH have an excellent prognosis, and are mostly<br>treated with local therapy. Multisystem LCH is subdivided into low risk and high risk groups. A 6-week course of<br>PRED/VBL is recommended for all patients with MS-LCH. Further therapy depends on the response to the initial<br>course, and risk group of the patient.</p> Histiocytosis, Langerhans cell histiocytosis, Treatment 77 80 http://ijbc.ir/browse.php?a_code=A-10-2-174&slc_lang=en&sid=1